An extensive literature review and analysis of five clinical trials suggests that discontinuing long-acting β2-agonist (LABA) therapy in adults and older children who have asthma that is controlled with a combination of inhaled corticosteroids and LABAs may be associated with increased asthma-related impairment, according to a new report.